Sarepta Therapeutics Announces Pricing of $100.7 Million Public Offering of Common Stock

  Sarepta Therapeutics Announces Pricing of $100.7 Million Public Offering of
  Common Stock

Business Wire

CAMBRIDGE, Mass. -- April 23, 2014

Sarepta Therapeutics, Inc. (Nasdaq: SRPT), a developer of innovative RNA-based
therapeutics, today announced that it has priced an underwritten public
offering of an aggregate of 2,650,000 shares of its common stock at a price to
the public of $38.00 per share. In addition, Sarepta has granted the
underwriters a 30-day option to purchase up to an additional 397,500 shares of
common stock on the same terms and conditions as the initial shares sold to
the underwriters. Sarepta anticipates the aggregate net proceeds from the
offering will be approximately $94.5 million, after deducting the underwriting
discount and estimated offering expenses payable by Sarepta, but excluding any
exercise of the underwriters’ option. The offering is expected to close on or
about April29, 2014, subject to customary closing conditions.

BofA Merrill Lynch, Morgan Stanley and Deutsche Bank Securities are acting as
joint book-running managers for the offering. In addition, Baird, William
Blair and Canaccord Genuity are acting as co-managers for the offering.

Sarepta intends to use the net proceeds from the offering for business
development, manufacturing, the continued development of eteplirsen and other
product candidates and other general corporate purposes.

The shares are being offered by Sarepta pursuant to an automatically effective
shelf registration statement that was previously filed with the Securities and
Exchange Commission (“SEC”). A preliminary prospectus supplement relating to
and describing the terms of the offering has been filed with the SEC and is
available on the SEC’s web site at Copies of the final prospectus
supplement and the accompanying prospectus relating to this offering, when
available, may be obtained from: BofA Merrill Lynch, 222 Broadway, New York,
NY 10038, Attn: Prospectus Department, or via email, at; or Morgan Stanley at 180 Varick Street,
Second Floor, New York, New York 10014, Attention: Prospectus Department.

This press release does not constitute an offer to sell or a solicitation of
an offer to buy any securities of Sarepta, nor shall there be any sale of
securities in any state or jurisdiction in which such an offer, solicitation
or sale would be unlawful prior to registration or qualification under the
securities laws of any such state or jurisdiction.

About Sarepta Therapeutics

Sarepta Therapeutics is focused on developing first-in-class RNA-based
therapeutics to improve and save the lives of people affected by serious and
life-threatening rare and infectious diseases. The Company's diverse pipeline
includes its lead program eteplirsen, for Duchenne muscular dystrophy, as well
as potential treatments for some of the world's most lethal infectious
diseases. Sarepta aims to build a leading, independent biotech company
dedicated to translating its RNA-based science into transformational
therapeutics for patients who face significant unmet medical needs.

Forward-Looking Statements and Information

This press release contains statements that are forward-looking, including the
statements about the completion timing and size of the proposed public
offering of Sarepta’s common stock, the expected net proceeds from the
offering and Sarepta’s expected use of the net proceeds from this offering,
within the meaning of Section 27A of the Securities Act of 1933 and Section
21E of the Securities Exchange Act of 1934. These forward-looking statements
involve risks and uncertainties many of which are beyond Sarepta’s control
including risk and uncertainties related to market conditions and satisfaction
of customary closing conditions related to the proposed public offering. There
can be no assurance that Sarepta will be able to complete the public offering
on the anticipated terms or at all. Applicable risks also include those that
are included in the “Risk Factors” section of Sarepta’s Annual Report on Form
10-K for the year ended December 31, 2013 and any subsequent SEC filings
including the final prospectus supplement related to the proposed offering to
be filed with the SEC. Any forward-looking statement in this press release
represents Sarepta’s views only as of the date of this press release and
should not be relied upon as representing its views as of any subsequent date.
Sarepta does not undertake any obligation to publicly update its
forward-looking statements based on events or circumstances after the date
hereof except as required by applicable law.


Sarepta Investor Contact:
Erin Cox, 617-274-4014
Sarepta Media Contact:
Jim Baker, 617-274-4010
Press spacebar to pause and continue. Press esc to stop.